{"id":14123,"date":"2022-09-12T11:22:46","date_gmt":"2022-09-12T09:22:46","guid":{"rendered":"https:\/\/latam.patiadiabetes.com\/diabegen\/"},"modified":"2022-09-12T12:15:37","modified_gmt":"2022-09-12T10:15:37","slug":"diabegen","status":"publish","type":"page","link":"https:\/\/latam.patiadiabetes.com\/en\/diabegen\/","title":{"rendered":"DIABEgen"},"content":{"rendered":"

DIABEgen<\/h1>\n<\/div>
<\/div><\/div><\/div>

\"gen\u00e9tica\"foto_padre_hijo\"<\/h2>\n

<\/h2>\n

<\/h2>\n

<\/h2>\n

Precision medicine for type 2 diabetes<\/h2>\n

Patia presents diabegen\u2122, a genomic tool that analyzes the main genetic variants associated with type 2 diabetes and offers the physician individualized considerations for a precise intervention in the management of the disease.<\/p>\n

In recent years, multiple scientific publications have described genotype\/phenotype associations in the development of type 2 diabetes and its complications.<\/p>\n

Patia<\/b> has selected genetic variants associated with certain glycemic features and clinical implications, to provide relevant information for the management of type 2 diabetes<\/p>\n

Genomics<\/b> for<\/b> intervention<\/b><\/h2>\n

Type 2 diabetes is a complex disease, for which direct and indirect genotype-phenotype associations have been identified: genotype\/symptomatology of the disease, genotype\/cellular functions<\/p>\n

A sample of the patient’s DNA provides useful information for matching treatment to the patient’s medical history and other complementary tests.<\/p>\n

Scientific<\/b> reliability<\/b><\/h2>\n

diabe<\/b>gen\u2122<\/b> has been developed in collaboration with scientists and endocrinologists at The Broad Institute of MIT and Harvard, (Cambridge, USA) and The Massachusetts General Hospital (Boston, USA):<\/p>\n

    \n
  • Sci Rep 2019, 9(1):2748.<\/li>\n
  • Nature 2014, 506(7486):97-101.<\/li>\n
  • JAMA 2014,311(22):2305-2314.<\/li>\n
  • Nat Genet. 2014, 46(3):234-244.<\/li>\n
  • Nat Genet. 2012, 44(9):981-990.<\/li>\n
  • PLoS Genet. 2015,11(12):e1005696.<\/li>\n<\/ul>\n<\/div>
    <\/div><\/div><\/div>

    diabe<\/b>gen\u2122<\/b> analyses genetic polymorphisms, selected for their relevant association with type 2 diabetes<\/p>\n

    \"medicina<\/p>\n<\/div>

    <\/div><\/div><\/div>

    \"\"<\/p>\n<\/div>

    <\/div><\/div><\/div>

    Genotype<\/i> information<\/i>, <\/i>along<\/i> with<\/i> clinical<\/i> criteria<\/i>, <\/i>is<\/i> a <\/i>powerful<\/i> tool<\/i> in <\/i>the<\/i> hands<\/i> of<\/i> the<\/i> physician<\/i> for<\/i> the<\/i> management<\/i> of<\/i> the<\/i> patient<\/i> diagnosed<\/i> with<\/i> type<\/i> 2 diabetes <\/i>or<\/i> pre-diabetes<\/i>\u201d<\/i><\/p>\n

    Mirella G. Zulueta, MD, PhD <\/b>Patia’s Medical Director<\/p>\n

    Recommendations<\/b> informed<\/b> by<\/b> genotype<\/b><\/h2>\n

    The results report provides relevant information for the physician on lifestyle (with specific suggestions for nutrition and physical exercise), supplements, pharmacological indications and other clinical tests to be assessed in the patient’s entire medical history.<\/p>\n

    Nutrition<\/b><\/h2>\n

    Optimal nutrients to be included in the patient’s eating habits and others to be excluded from their diet<\/p>\n

    diabe<\/b>gen<\/b>\u2122<\/b>\u00a0 <\/b>identifies genetic polymorphisms to enable genotype-informed personalization of patient’s diet.<\/p>\n

    Physical<\/b> activity<\/b><\/h2>\n

    Specific indications of recommended exercise type according to genotype (aerobic or anaerobic). With diabe<\/b>gen<\/b>\u2122<\/b> the identification of polymorphisms associated with the impact of physical activity on glycemic homeostasis facilitates the personalization of the appropriate physical exercise.<\/p>\n

    Supplements<\/b><\/h2>\n

    Food supplements containing minerals and vitamins suitable for intervention. diabe<\/b>gen<\/b>\u2122<\/b> identifies which dietary supplements may be beneficial to complement patient\u2019s diet.<\/p>\n

    Pharmacology and <\/b>Other<\/b> medical test <\/b><\/h2>\n

    The identification with diabe<\/b>gen<\/b>\u2122<\/b> of several genetic polymorphisms associated with response to different drugs facilitates the selection of the most precise drug treatment. Indication of the patient’s suitability and response to certain treatments and suggested complementary laboratory tests.<\/p>\n

    \"\" \"\"<\/p>\n<\/div>

    <\/div><\/div><\/div>

    Clinical indication :<\/p>\n

    Individual <\/b>diagnosed<\/b> with<\/b> DT2, <\/b>pre-diabetes<\/b> or<\/b> high<\/b> glycemia<\/b><\/p>\n

    Sampling :<\/p>\n

    Buccal<\/b> epithelial<\/b> cells<\/b> (<\/b>swab<\/b>) <\/b>or<\/b> blood<\/b> (<\/b>EDTA<\/b> tube<\/b>) <\/b><\/p>\n

    Results available in:<\/p>\n

    12 <\/b>business<\/b>\u00a0 <\/b>days<\/b><\/p>\n<\/div>

    <\/div><\/div><\/div>

    <\/h2>\n<\/div>
    <\/div><\/div><\/div>

    <\/h3>\n
    \n
    \n

    I am a healthcare professional and I want to know more about DIABEgen.<\/h3>\n
    \n

    <\/p>

      <\/ul><\/div>\n
      \n
      \n\n\n\n\n\n\n\n<\/div>\n

      Persona de contacto (*)\n<\/p>\n

      <\/span>\n<\/p>\n

      Instituci\u00f3n\n<\/p>\n

      <\/span>\n<\/p>\n

      Localidad\n<\/p>\n

      <\/span>\n<\/p>\n

      Pa\u00eds\n<\/p>\n

      <\/span>\n<\/p>\n

      Tel\u00e9fono de contacto (*)\n<\/p>\n

      <\/span>\n<\/p>\n

      Email (*)\n<\/p>\n

      <\/span>\n<\/p>\n

      <\/span>\n<\/p>\n

      \u00bfC\u00f3mo has conocido PromarkerD?:
      \n